AIDS Res Ther by Mecha, Jared O. et al.
Mecha et al. AIDS Res Ther  (2016) 13:38 
DOI 10.1186/s12981-016-0122-y
RESEARCH
Trends in clinical characteristics 
and outcomes of Pre-ART care at a large HIV 
clinic in Nairobi, Kenya: a retrospective cohort 
study
Jared O. Mecha1*, Elizabeth N. Kubo1, Lucy W. Nganga2, Peter N. Muiruri3, Lilian N. Njagi1, 
Immaculate N. Mutisya4, Justine J. Odionyi1, Syokau C. Ilovi1, Mary Wambui1, Christopher Githu2, 
Richard Ngethe2, Elizabeth M. Obimbo1 and Zipporah W. Ngumi1
Abstract 
Background: The success of antiretroviral therapy in resource-scarce settings is an illustration that complex health-
care interventions can be successfully delivered even in fragile health systems. Documenting the success factors in 
the scale-up of HIV care and treatment in resource constrained settings will enable health systems to prepare for 
changing population health needs. This study describes changing demographic and clinical characteristics of adult 
pre-ART cohorts, and identifies predictors of pre-ART attrition at a large urban HIV clinic in Nairobi, Kenya.
Methods: We conducted a retrospective cohort analysis of data on HIV infected adults (≥15 years) enrolling in 
pre-ART care between January 2004 and September 2015. Attrition (loss to program) was defined as those who died 
or were lost to follow-up (having no contact with the facility for at least 6 months). We used Kaplan-Meier survival 
analysis to determine time to event for the different modes of transition, and Cox proportional hazards models to 
determine predictors of pre-ART attrition.
Results: Over the 12 years of observation, there were increases in the proportions of young people (age 15 to 
24 years); and patients presenting with early disease (by WHO clinical stage and higher median CD4 cell counts), 
p = 0.0001 for trend. Independent predictors of attrition included: aHR (95% CI): male gender 1.98 (1.69–2.33), 
p = 0.0001; age 20–24 years 1.80 (1.37–2.37), p = 0.0001), or 25–34 years 1.22 (1.01–1.47), p = 0.0364; marital sta-
tus single 1.55 (1.29–1.86), p = 0.0001) or divorced 1.41(1.02–1.95), p = 0.0370; urban residency 1.83 (1.40–2.38), 
p = 0.0001; CD4 count of 0–100 cells/µl 1.63 (1.003–2.658), p = 0.0486 or CD4 count >500 cells/µl 2.14(1.46–3.14), 
p = 0.0001.
Conclusions: In order to optimize the impact of HIV prevention, care and treatment in resource scarce settings, 
there is an urgent need to implement prevention and treatment interventions targeting young people and patients 
entering care with severe immunosuppression (CD4 cell counts <100 cells/µl). Additionally, care and treatment pro-
grammes should strengthen inter-facility referrals and linkages to improve care coordination and prevent leakages in 
the HIV care continuum.
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Background
The HIV prevention and care continuum is a valuable 
framework for assessing linkage to, and retention in care, 
antiretroviral therapy and viral suppression for people 
living with HIV infection. Examining care and treatment 
programs in SSA (Sub-Saharan Africa) has revealed sig-
nificant leakages across this continuum. For instance, 
only 80% of people testing positive for HIV are success-
fully linked to care within 3  months of diagnosis [1]. 
Worryingly, retention in care prior to ART (Antiretro-
viral Therapy) initiation is lower (45–75%), compared to 
retention after starting ART [2–4].
Attrition from care during this phase has been linked to 
early morbidity and mortality in the ART phase [5]. The 
reasons for low retention in pre-ART care include trans-
portation costs, distance to health care facilities, young 
age, male gender, unemployment, lower education levels, 
stigma and fear of disclosure of HIV status [6]. Improv-
ing HIV/AIDS care and treatment program outcomes is 
dependent on successful linkage of patients to pre-ART 
care and retention in care until ART initiation [7]. The 
current WHO (World Health Organisation) HIV treat-
ment guidelines recommend ART initiation in all patients 
with HIV irrespective of clinical stage or CD4 cell count 
[8]. Consequently, although the proportion of people in 
pre-ART care will be markedly reduced and the dura-
tion of pre-ART care shortened significantly, implemen-
tation of the new guidelines will not entirely eliminate a 
pre-ART phase. Evaluating the changing characteristics 
of pre-ART cohorts and how these characteristics influ-
ence retention and care outcomes can offer insights on 
designing interventions to improve retention and engage-
ment in care prior to initiation of ART. Entry into pre-
ART may also be viewed as a surrogate of effectiveness of 
population level prevention interventions.
We analysed routinely collected longitudinal clinical 
data to describe changing demographic and clinical char-
acteristics of pre-ART cohorts over a 12 year period at a 
large urban HIV clinic in Kenya. We further described 
how these characteristics influence pre-ART attrition.
Methods
Study site and population
The Kenyatta National Hospital Comprehensive Care 
Centre (KNH CCC) offers ambulatory HIV care and 
treatment services mainly to residents of Nairobi city and 
neighbouring urban and peri-urban settlements. Most of 
the funds for these services were provided by the United 
States President’s Emergency Plan for AIDS Relief (PEP-
FAR) through the University of Nairobi’s AIDS Care 
and Treatment Services (2003–2010) and the Centres of 
Excellence Project (2010–2016). Patients registered at 
the KNH CCC are usually referred from the on-site HIV 
testing services (Voluntary Counselling and Testing—
VCT, and Provider Initiated Testing and Counselling—
PITC) and as formal and informal (walk-in) referrals. 
Most services are provided by a multi-disciplinary team 
of primary care providers. Patients with complications 
are booked for review by specialists. Outpatient HIV care 
is offered at no cost to the patients.
The criteria for pre-ART care and the organization and 
range of services changed, in line with national guidelines 
and better understanding of HIV care and treatment, 
during the 12 year follow-up period under review. Briefly, 
care comprises of registration and initial evaluation to 
assess eligibility for ART (WHO clinical stage and CD4 
cell count), targeted additional laboratory tests, group 
and individual counselling and treatment literacy, cotri-
moxazole prophylaxis; symptom-based tuberculosis (TB) 
screening and isoniazid prophylaxis (since 2014); linkage 
to psychosocial support groups; and regular follow-up 
(every 3–6  months depending on closeness to the ART 
eligibility threshold).
Data collection, management and analysis
Data collection
Prior to 2013, providers recorded patient health infor-
mation using semi-structured clinical encounter forms. 
Through an extensive exercise of data abstraction and 
reconstruction using fully structured clinical encoun-
ter forms, trained data assistants transferred key health 
information into a customized electronic health records 
(EHR) system. After 2013, all patient encounter sessions 
were entered directly into the EHR system in a paperless 
operating environment.
Data is captured at the point of care by all service 
providers. The EHR system has a data mining function-
ality that enables routine data quality checks using pre-
defined clinical and program indicators.
Study design, study participants and setting
We conducted a retrospective cohort analysis of prospec-
tively collected data on HIV infected adults (≥15 years) 
enrolling at the HIV Clinic between January 1, 2004 and 
September 30, 2015. The data analysis date was October 
1, 2015. Patient records were excluded if: (i) they were 
missing the main outcome or explanatory variables of 
interest such as gender, age or date of birth; (ii) the enrol-
ment date was before January 1, 2004, or after September 
30, 2015; and (iii) age less than 15 years at enrolment.
Outcome definition
The outcome variable of interest was mode of transition 
from pre-ART care into one of these mutually exclu-
sive categories: (i) started ART (irrespective of ARV 
treatment outcome); (ii) lost to program [died or lost 
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to follow-up (no contact with the facility for at least 
6 months)]; (iii) transferred to another facility before ini-
tiation of ART; or (iv) remained in care at the end of the 
study period. The main explanatory variable was the year 
of entry into pre-ART care. Other covariates of interest 
were demographic and clinical characteristics at enrol-
ment into pre-ART care.
Data extraction
We extracted data from IQCare, an open-source, 
browser-based, EHR system custom-designed for HIV 
care and treatment programs in resource limited set-
tings. The EHR has a data mining functionality, IQTools, 
which facilitates data quality assurance and extrac-
tion for reporting, quality improvement and operations 
research. Extracted data were exported to Microsoft 
Access (Microsoft Corporation, California) for analysis 
in SAS version 9.4 (SAS Institute, Cary, North Carolina). 
Extracted variables included pre-ART outcomes, year of 
enrolment, demographic characteristics such as gender, 
age at care start, marital status and residency (urban/
rural). Clinical characteristics included CD4 cell count, 
WHO clinical stage and opportunistic infections at 
enrolment into pre-ART care. Other variables of interest 
were patient source, and date of HIV diagnosis.
To ensure confidentiality, data were stripped of patient 
identifiers such as names, home address and telephone 
numbers. In addition, the data analysts did not have 
access to individual patient data in the EHR and had no 
way of linking extracted records to any individual patient. 
Patient serial numbers were, however maintained for 
ease of merging datasets from different sources.
Statistical analysis
The main outcome variable was mode of transition out 
of pre-ART care. These were: started ART, attrition (lost 
to follow-up or death) and transferred to another facility. 
Some patients had not yet transitioned out of pre-ART 
care by the time of these analyses.
Covariates included demographic and clinical charac-
teristics that could potentially influence mode of transi-
tion from pre-ART care. These were measured at care 
entry. Descriptive analyses were performed for these 
characteristics. Categorical variables were summarized 
using proportions while continuous variables were sum-
marized using means and standard deviations or medians 
and interquartile ranges (IQR). The Chi square test was 
used to compare proportions, Mann-Whitney U test to 
compare medians and T-test to compare means. All sta-
tistical tests were two-sided at an alpha (α) level of 0.05.
In the time to event analyses (Kaplan-Meier survival 
analysis), the event of interest was pre-ART attrition. 
Patients without the event of interest i.e. those who 
started ART or remained in pre-ART care were cen-
sored while patients who transferred to another facility 
(n = 46) were excluded from the time to event analysis. 
We used Cox proportional hazards models to determine 
effect of patient characteristics at care entry on pre-ART 
attrition. A category for missing data was created in all 
covariates and incorporated in the Cox proportional haz-
ards models.
To test the global null hypothesis that all parameter 
estimates for the covariates included in the model are 
equal to zero, we used the Likelihood Ratio, Score and 
Wald’s Chi square tests. Unadjusted and adjusted haz-
ard ratios with 95% confidence intervals and p-values 
were generated and used to determine the patient char-
acteristics that were independently associated with pre-
ART attrition. Wald confidence limits were used for all 
Cox univariate/multivariate analyses. Data were analysed 
using SAS software 9.2 (SAS Institute, Cary, NC).
Results
Between January 1, 2004 and September 30, 2015, 8630 
adults were enrolled into HIV care, contributing a total of 
88,126 patient-months of follow-up during 141  months 
of follow-up. At analysis, 7663 (88.8%) started ART, 236 
(2.70%) remained in pre-ART care, 685 (7.9%) were lost 
to program, and 46 (0.5%) transferred to other providers 
(Fig. 1).
Table 1 shows patient enrolment characteristics strati-
fied by pre-ART care start cohort. Overall, median age 
at enrolment was 37 years (IQR 31–44), and more than 
60% of the patients were female. More than three quar-
ters of the patients (78.2%) were urban residents. The on-
site VCT centre was the main source of patients (43.4%). 
Over half of the patients (54.5%) were classified as WHO 
Clinical Stage I and II, and the median CD4 cell count at 
enrolment was 257 cells per cubic millimetre (IQR 109–
460). Nearly a third (29.0%) of new enrolees had a CD4 
count ≤200 cells per cubic millimetre. A tenth of patients 
had previous or current tuberculosis (TB) at enrolment.
Time trends for enrolment characteristics are presented 
in Table 1. There was a slight overall decline in the pro-
portion of females newly entering care during the obser-
vation period (p =  0.0106 for trend). The proportion of 
adolescents and young adults (age 15–24  years) newly 
entering care increased progressively from 2.2% in 2004–
05, to 11.7% in 2014–15 (p = 0.0001 for trend). The pro-
portion of patients newly entering care from the on-site 
VCT progressively increased from 34.4% in 2004–05, to 
50.8% in 2014–15 (p = 0.0001 for trend).
On average, 45% of patients were enrolled into care the 
same year they were diagnosed to be HIV positive. The 
proportion of patients enrolling in care in the same year 
that they were diagnosed to be HIV positive declined 
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from 43.7% in 2004–05, to 36.8% in 2014–15 (p = 0.0412 
for trend).
There was a progressive increase in the proportion of 
patients presenting early (in WHO Stage 1&2) for care 
(from 38.7% in 2004–05, to 57.2% in 2014–15, p = 0.0001 
for trend). Similarly, there was an overall increase in 
median CD4 cell count at enrolment (from 178 to 259 
cells/µl, p = 0.0001 for trend).
Figure  2 shows the Kaplan-Meier curves for transi-
tion from pre-ART care. Median time to ART initiation 
was 2 months while median time to loss to program was 
96 months.
Table 2 shows rates of attrition per 1000 patient-months 
of follow up for the different enrolment characteristics. 
More attrition was experienced by males compared to 
females, young adults (20–24  years) compared to those 
aged 35–44  years, single and non-documented marital 
status compared to married couples, urban and non-doc-
umented residency compared to rural, and patients who 
entered care with a high (>500 cells/µl) CD4 count com-
pared to those with a CD4 count of 251–350 cells/µl. On 
the other hand, less attrition was noted among patients 
whose source of entry into care was the PMTCT or TB 
clinics compared to the on-site VCT, patients with TB at 
entry into care compared to those without TB. Addition-
ally, patients with a documented opportunistic condition 
experienced less attrition compared to those without an 
opportunistic infection at entry into care.
Overall, risk factors for pre-ART attrition included: 
aHR (95% CI); male gender 1.98 (1.69–2.33), p = 0.0001 
compared to female; age 20–24  years 1.80 (1.37–2.37), 
p = 0.0001, or 25–34 years 1.22 (1.01–1.47), p = 0.0364 
compared to age 35–44  years; marital status single 1.55 
(1.29–1.86), p  =  0.0001 or divorced 1.41 (1.02–1.95), 
p =  0.0370 compared to married; urban residency 1.83 
(1.40–2.38), p =  0.0001 compared to rural; CD4 count 
of 0–100 cells/µl 1.63 (1.003–2.658), p = 0.0486 or CD4 
count >500 cells/µl 2.14 (1.46–3.14), p  =  0.0001 com-
pared to 251–350 cells/µl. Non-documentation of: 
marital status 1.53 (1.08–2.17), p  =  0.0164; care entry 
point 1.52 (1.21–1.90), p  =  0.0003; clinical stage 10.5 
(8.03–13.6), p = 0.0001; and CD4 count 2.98 (2.00–4.44), 
p =  0.0001 also predicted attrition. On the other hand, 
factors which rendered attrition less likely included: aHR: 
(95% CI): patient referrals from the PMTCT clinic: 0.54 
(0.41–0.71), p = 0.0001, and TB clinic: 0.55 (0.39–0.78), 
p = 0.0007 compared to on-site VCT (Table 3).
Discussion
We have described overall trends in pre-ART patient 
characteristics and predictors of attrition prior to initia-
tion of ART over a 12 year period in a large urban clinic 
cohort in Kenya. At analysis, nearly 89% of patients 
enrolled into pre-ART care had started ART, and the 
overall loss to program was approximately 8%.
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Table 1 Enrolment characteristics by care start cohort
Year of enrol-
ment
2004–05 2006–07 2008–09 2010–11 2012–13 2014–15 Overall Chi Square 
for trend  
p value
n = 789 n = 1435 n = 1538 n = 1438 n = 1830 n = 1600 n = 8630
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Gender
Female n (%) 493 (62.5) 920 (64.1) 995 (64.7) 914 (63.6) 1118 (61.1) 968 (60.5) 5408 (62.7) 0.0106
Age (in yrs.)
Mean (sd) 38.2 (8.6) 38.3 (9.0) 37.6 (9.5) 37.3 (9.8) 37.3 (10.0) 36.8 (10.7) 37.5 (9.7) 
Median (IQR) 37 (32–43) 37 (32–44) 37 (31–43) 36 (30–43) 37 (30–44) 36 29–44) 37 (31–44) 
Age group n (%)
15–19 3 (0.4) 8 (0.6) 21 (1.4) 19 (1.3) 44 (2.4) 45 (2.8) 140 (1.6) 0.0001
20–24 14 (1.8) 46 (3.2) 66 (4.3) 93 (6.5) 118 (6.5) 143 (8.9) 480 (5.6)
25–34 275 (34.9) 478 (33.3) 528 (34.4) 506 (35.2) 583 (31.9) 514 (32.1) 2884 (33.4)
35–44 335 (42.5) 587 (40.9) 590 (38.3) 505 (35.1) 663 (36.2) 525 (32.8) 3205 (37.2)
45–54 121 (15.4) 239 (16.7) 254 (16.5) 233 (16.2) 328 (18) 282 (17.6) 1457 (16.9)
55+ 41 (5.2) 77 (5.4) 79 (5.1) 82 (5.7) 94 (5.1) 91 (5.7) 464 (5.4)
Marital status n (%)
Single 159 (20.2) 281 (19.6) 295 (19.2) 339 (23.6) 500 (27.3) 477 (29.8) 2051 (23.8) 0.0034
Married 473 (60) 837 (58.3) 942 (61.3) 834 (58) 946 (51.7) 738 (46.1) 4770 (55.3)
Divorced/sepa-
rated
38 (4.8) 105 (7.3) 93 (6.1) 90 (6.3) 169 (9.2) 171 (10.7) 666 (7.7)
Widowed 91 (11.5) 165 (11.5) 152 (9.9) 116 (8.1) 171 (9.3) 142 (8.9) 837 (9.7)
Not documented 28 (3.6) 47 (3.3) 56 (3.6) 59 (4.1) 44 (2.4) 72 (4.5) 306 (3.6)
Residency n (%)
Rural 185 (23.5) 257 (17.9) 296 (19.3) 187 (13.0) 186 (10.2) 62 (3.9) 1173 (13.6) 0.0001
Urban 537 (68.1) 1081 (75.3) 1145 (74.5) 1182 (82.2) 1444 (78.9) 1362 (85.1) 6751 (78.2)
Not documented 67 (8.5) 97 (6.8) 97 (6.3) 69 (4.8) 200 (10.9) 176 (11.0) 706 (8.2)
Patient source n (%)
VCT 271 (34.4) 588 (41) 650 (42.3) 628(4 3.7) 793 (43.3) 812(5 0.8) 3742 (43.4) 0.0001
PMTCT 202 (25.6) 296 (20.6) 293 (19.1) 232 (16.1) 159 (8.7) 107 (6.7) 1289 (14.9)
TB clinic 87 (11) 189 (13.2) 164 (10.7) 189 (13.1) 90 (4.9) 1 (0.1) 720 (8.3)
In-patient 59 (7.5) 114 (7.9) 129 (8.4) 98 (6.8) 174 (9.5) 190 (11.9) 764 (8.9)
Out-patient 9 (1.1) 16 (1.1) 14 (0.9) 22 (1.5) 63 (3.4) 11 (0.7) 135 (1.6)
Other facility 13 (1.7) 32 (2.2) 29 (1.9) 28 (2) 169 (9.2) 32 (2) 303 (3.5)
Other source 42 (5.3) 67 (4.7) 85 (5.5) 69 (4.8) 215 (11.8) 416(26) 894 (10.4)
Not documented 106 (13.4) 133 (9.3) 174 (11.3) 172 (12) 167 (9.1) 31 (1.9) 783 (9.1)
HIV diagnosis n(%)
YoEnr ≠ YoDg 48 (6.1) 163 (11.4) 226 (14.7) 247 (17.2) 343 (18.7) 234 (14.6) 1261 (14.6) 0.0412
YoEnr = YoDg 345 (43.7) 737 (51.4) 760 (49.4) 684 (47.6) 787 (43.0) 588 (36.8) 3901 (45.2)
YoDg not docu-
mented
396 (50.2) 535 (37.3) 552 (35.9) 507 (35.3) 700 (38.3) 778 (48.6) 3468 (40.2)
Clinical stage n (%)
Stage 1&2 305 (38.7) 650 (45.3) 890 (57.9) 899 (62.5) 1043 (57) 915 (57.2) 4702 (54.5) 0.0001
Stage 3&4 448 (56.8) 742 (51.7) 608 (39.5) 501 (34.8) 600 (32.8) 440 (27.5) 3339 (38.7)
Not documented 36 (4.6) 43 (3) 40 (2.6) 38 (2.6) 187 (10.2) 245 (15.3) 589 (6.8)
CD4 count
Median (IQR) 178 (67–330) 197 (80–380) 273 (128–458) 320 (158–507) 279 (111–490) 259 (101–483) (257) (109–460)
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Consistent with other studies [9, 10], most of the 
patients newly enrolling into care were young females 
reflecting the disproportionate burden of HIV infec-
tion in this group. However, the extent of this disparity, 
as measured using care and treatment data, has come 
under scrutiny. In a recent innovative analysis, Auld et al 
[11] compared the female to male ratio among new ART 




2004–05 2006–07 2008–09 2010–11 2012–13 2014–15 Overall Chi Square 
for trend  
p value
n = 789 n = 1435 n = 1538 n = 1438 n = 1830 n = 1600 n = 8630
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
CD4 group n (%)
0–100 145 (18.4) 303 (21.1) 192 (12.5) 170 (11.8) 332 (18.1) 290 (18.1) 1432 (16.6) 0.0001
101–200 86 (10.9) 214 (14.9) 166 (10.8) 182 (12.7) 232 (12.7) 189 (11.8) 1069 (12.4)
201–250 50 (6.3) 67 (4.7) 89 (5.8) 86 (6) 106 (5.8) 92 (5.8) 490 (5.7)
251–350 43 (5.5) 142 (9.9) 145 (9.4) 156 (10.9) 188 (10.3) 148 (9.3) 822 (9.5)
351–500 51 (6.5) 140 (9.8) 166 (10.8) 216 (15) 241 (13.2) 168 (10.5) 982 (11.4)
>500 47 (6) 159 (11.1) 194 (12.6) 288 (20) 341 (18.6) 285 (17.8) 1314 (15.2)
Not documented 367 (46.5) 410 (28.6) 586 (38.1) 340 (23.6) 390 (21.3) 428 (26.8) 2521 (29.2)
Opportunistic infections n (%)
TB 91 (11.5) 178 (12.4) 161 (10.5) 144 (10) 231 (12.6) 133 (8.3) 938 (10.9) 0.0726
PCP 33 (4.2) 60 (4.2) 73 (4.8) 74 (5.2) 89 (4.9) 26 (1.6) 355 (4.1) 0.0271
Cryptococcal 
disease
4 (0.5) 8 (0.6) 16 (1) 9 (0.6) 15 (0.8) 9 (0.6) 61 (0.7) 0.7077
Oral candidiasis 59 (7.5) 106 (7.4) 42 (2.7) 38 (2.6) 38 (2.1) 35 (2.2) 318 (3.7) 0.0001
Oesophageal 
candidiasis
1 (0.1) 8 (0.6) 6 (0.4) 11 (0.8) 4 (0.2) 7 (0.4) 37 (0.4) 0.9132
Kaposi’s sarcoma 12 (1.5) 12 (0.8) 20 (1.3) 12 (0.8) 8 (1) 11 (0.7) 85 (1) 0.1126
Other OIa 197 (25) 423 (29.5) 441 (28.7) 502 (34.9) 648 (35.4) 402 (25.1) 2613 (30.3) 0.0162
Any OIb 301 (38.2) 601 (41.9) 617 (40.1) 656 (45.6) 863 (47.2) 519 (32.4) 3557 (41.2) 0.8563
Presenting symptoms n (%)
Abdominal pain 38 (4.8) 53 (3.7) 55 (3.6) 57 (4) 76 (4.2) 85 (5.3) 364 (4.2) 0.089
Headache 50 (6.3) 75 (5.2) 97 (6.3) 84 (5.8) 111 (6.1) 116 (7.3) 533 (6.2) 0.21
Cough 167 (21.2) 206 (14.4) 264 (17.2) 217 (15.1) 315 (17.2) 284 (17.8) 1453 (16.8) 0.8723
Chest pain 47 (6) 1 (2.9) 68 (4.4) 46 (3.2) 65 (3.6) 74 (4.6) 341 (4) 0.6866
Any symptom 389 (49.3) 643 (44.8) 662 (43) 526 (36.6) 813 (44.4) 862 (53.9) 3895 (45.1) 0.0369
Italic values indicate overall summary statistics
VCT voluntary counselling and testing; PCP pneumocystis carinii pneumonia
a Other OIs includes all major and minor OIs not listed in table PMTCT prevention of mother to child transmission
b Any OIs includes both OIs listed and not listed in table TB tuberculosis
Transferred out of facility
Arion (Died or LTFu)
Started ART























Fig. 2 K-M curves plotted for transition from pre-ART care
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Table 2 Attrition (/1000patient-months of follow-up) by enrolment characteristics
Enrolment  
characteristic
Numb dead  
or LTFu
Total months  
in care
Attrition (/1000 patient− 
mths of follow-up) (95% CI)
Overall 685 88,126 7.8 (7.2–8.4)
Gender
Female 363 58,886 6.2 (5.5–6.8)
Male 322 29,240 11.0 (9.8–12.2)
Age group
15–19 12 918 13.1 (5.7–20.4)
20–24 86 5191 16.6 (13.1–20.0)
25–34 295 36,680 8.0 (7.1–9.0)
35–44 209 29,531 7.1 (6.1–8.0)
45–54 68 12,454 5.5 (4.2–6.8)
55Plus 15 3352 4.5 (2.2–6.7)
Marital status
Single 230 18,942 12.1 (10.6–13.7)
Married 335 52,154 6.4 (5.7–7.1)
Divorced 43 5393 8.0 (5.6–10.3)
Widowed 39 7934 4.9 (3.4–6.5)
Not documented 38 3703 10.3 (7.0–13.5)
Residency
Rural 65 14,908 4.4 (3.3–5.4)
Urban 553 66,661 8.3 (7.6–9.0)
Not documented 67 6557 10.2 (7.8–12.7)
Point of entry into care
VCT 327 38,075 8.6 (7.7–9.5)
PMTCT 66 17,440 3.8 (2.9–4.7)
TB Clinic 37 9731 3.8 (2.6–5.0)
Inpatient 46 6150 7.5 (5.3–9.6)
Outpatient 12 1061 11.3 (4.9–17.7)
Other facility 11 1049 10.5 (4.3–16.7)
Other source 63 4280 14.7 (11.1–18.3)
Not documented 123 10,340 11.9 (9.8–14.0)
YoEnr vs YoDg
YoEnr ≠ YoDg 59 10,027 5.9 (4.4–7.4)
YoEnr = YoDg 257 45,336 5.7 (5.0–6.4)
YoDg not documented 369 32,763 11.3 (10.1–12.4)
Disease stage (WHO)
Stage 1–2 354 62,334 5.7 (5.1–6.3)
Stage 3–4 119 24,099 4.9 (4.1–5.8)
Not documented 212 1693 125.2 (109.5–141.0)
CD4 count
0–100 37 6218 6.0 (4.0–7.9)
101–200 28 5561 5.0 (3.2–6.9)
201–250 8 2917 2.7 (0.8–4.6)
251–350 31 9506 3.3 (2.1–4.4)
351–500 85 19,328 4.4 (3.5–5.3)
> 500 216 34,222 6.3 (5.5–7.2)
Not documented 280 10,374 27.0 (23.9–30.1)
TB
No 654 80,707 8.1 (7.5–8.7)
Yes 31 7419 4.2 (2.7–5.6)
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population. In this analysis of data from 12 countries, 
17–73% fewer men (aged above 15 years) were enrolling 
in ART compared to females. Possibly, HIV infected men 
are not accessing care to the same extent as women. This 
may be due, in part, to lower emphasis on men’s health 
in media campaigns, fewer opportunities for males to be 
tested for HIV, and probably, greater perception of stigma 
and discrimination among men [12].
Worryingly, the proportion of adolescents and young 
adults (age 15–24  years) newly entering care increased 
five-fold during the observation period. Similar findings 
have been documented previously. A study conducted in 
Kenya showed an increase in the number of HIV infected 
older adolescents and youth (15–24 years) enrolling into 
care over a six-year period compared to younger ado-
lescents [13]. Another study following up adolescents 
and youth in 4 sub-Saharan countries documented a 6% 
increase in the number of youth aged 15–24 years enroll-
ing into HIV care (from 12% in 2005 to 18% in 2010) 
[14]. These findings can be attributed to the increase in 
HIV incidence that has been noted in this age group over 
the study period [15], as a result of underlying increased 
vulnerability to HIV infection, targeted HIV testing for 
youth and young adults [16–18].
On-site VCT services contributed the largest pro-
portion of new pre-ART enrolees in our cohort. For 
large busy hospitals, on-site VCT services offer excel-
lent opportunities for people to access HIV testing ser-
vices. Upward trends in the proportion of enrolments 
from the VCT were also documented in a prospective 
cohort analysis of adult patients in Tanzania [19], and 
in a multi-country retrospective data review of older 
HIV positive adults [20]. A recent retrospective study in 
Ethiopia however, reported an increase in the proportion 
of adults enrolling into care through PITC services over 
time [21]. However, this analysis was done at a time when 
PITC services were being scaled up in the country which 
may have biased the findings. PITC has been shown to 
have a higher yield in identifying later stage HIV positive 
patients [22].
Overall, about 45% of patients were linked to HIV care 
within the same year of diagnosis. Although this falls well 
below the 80% national average linked within 3 months of 




Numb dead  
or LTFu
Total months  
in care
Attrition (/1000 patient− 
mths of follow-up) (95% CI)
PCP
No 662 83,205 8.0 (7.4–8.6)
Yes 23 4921 4.7 (2.8–6.6)
Oral candidiasis
No 673 84,681 7.9 (7.3–8.5)
Yes 12 3445 3.5 (1.5–5.5)
Other OI
No 504 51,738 9.7 (8.9–10.6)
Yes 181 36,388 5.0 (4.3–5.7)
Any OI
No 472 44,453 10.6 (9.7–11.6)
Yes 213 43,673 4.9 (4.2–5.5)
Cryptococcal disease
No 683 87,641 7.8 (7.2–8.4)
Yes 2 485 4.1 (0–9.8)
Oesophageal candidiasis
No 679 87,725 7.7 (7.2–8.3)
Yes 6 401 15.0 (3.1–26.8)
Kaposi’s sarcoma
No 681 87,567 7.8 (7.2–8.4)
Yes 4 559 7.2 (0.2–14.1)
Lymphoma
No 684 88,084 7.8 (7.2–8.3)
Yes 1 42 23.8 (0–69.9)
VCT voluntary counselling and testing; PMTCT prevention of mother to child transmission; TB tuberculosis; PCP pneumocystis carinii pneumonia; OI opportunistic 
infection
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documented from studies in other SSA settings, which 
range from 38% [22] to 68% [24] who are linked to care 
within six months of diagnosis.
We noted an increase in the proportion of patients ini-
tiating care in early disease (WHO stage I & II), and with 
higher CD4 cell counts. Similar temporal trends have 
been observed in several SSA countries in the last dec-
ade [19, 25–28]. This is a positive program indicator. It 
is expected that early entry into care will translate into 
prompt initiation of ART prior to severe immune dam-
age [29].
Male gender, the youth (20–24  years), adults aged 
25–34  years, inadequate social support (defined as sin-
gle, or divorced marital status), urban residency, low CD4 
cell counts, and CD cell counts above 500 cells/µl were all 
associated with increased risk of loss to follow-up from 
pre-ART care.
Our analysis found patients with CD4 counts ≤100 
cells/µl to be at higher risk of attrition. This is in con-
trast to other studies which reported higher CD4 counts 
(>250 cells/µl) to be predictive of attrition [30, 31]. Our 
definition of attrition included both mortality and loss to 
follow up while the other studies referenced specifically 
focused on loss to follow up, hence the different findings. 
Indeed, patients with advanced immunosuppression are 
at increased risk of death [32]. These findings underscore 
the importance of initiating ART at higher CD4 counts. 
Our finding of CD4 counts >500 to be predictive of attri-
tion is consistent with that of other studies [30, 31].
Previous work has documented younger age (<35 years) 
to be predictive of pre-ART loss to follow up [30, 33–35]. 
Similarly, our analysis found evidence of higher attrition 
in the 20–24 and 25–34 years age groups.
Consistent with other findings, being single or divorced 
was predictive of attrition [34–36]. This possibly implies 
limited social and financial support mechanisms. Imple-
menting strategies that address social and economic 
Table 3 Hazard ratios for pre-ART attrition




HR (95% CI) p value HR (95% CI) p value
Gender
Female Ref Ref Ref Ref
Male 1.71 (1.47–1.99) 0.0001 1.98 (1.69–2.33) 0.0001
Age
15–19 1.75 (0.98–3.13) 0.0596 1.39 (0.76–2.54) 0.2833
20–24 2.55 (1.99–3.28) 0.0001 1.80 (1.37–2.37) 0.0001
25–34 1.25 (1.05–1.50) 0.0133 1.22 (1.01–1.47) 0.0364
35–44 Ref Ref Ref Ref
45–54 0.78 (0.59–1.02) 0.0683 0.77 (0.59–1.02) 0.0680
≥55 0.58 (0.34–0.98) 0.0416 0.68 (0.40–1.16) 0.1526
Marital status
Single 1.81 (1.53–2.14) 0.0001 1.55 (1.29–1.86) 0.0001
Married Ref Ref Ref Ref
Divorced 1.13 (0.82–1.55) 0.4533 1.41 (1.02–1.95) 0.0370
Widowed 0.72 (0.52–1.00) 0.0511 1.02 (0.73–1.44) 0.8907
Not documented 1.68 (1.20–2.36) 0.0024 1.53 (1.08–2.17) 0.0164
Residency
Rural Ref Ref Ref Ref
Urban 1.80 (1.39–2.32) 0.0001 1.83 (1.40–2.38) 0.0001
Not documented 2.18 (1.55–3.07) 0.0001 0.97 (0.68–1.39) 0.8573
Care entry point
VCT Ref Ref Ref Ref
PMTCT 0.47 (0.36–0.61) 0.0001 0.54 (0.41–0.71) 0.0001
TB clinic 0.48 (0.34–0.67) 0.0001 0.55 (0.39–0.78) 0.0007
In patient 0.82 (0.60–1.11) 0.2018 1.02 (0.74–1.40) 0.9082
Other facility 0.82 (0.45–1.50) 0.526 1.00 (0.54–1.85) 0.9937
Other sourcea 1.32 (1.02–1.69) 0.0334 0.99 (0.76–1.28) 0.9177
Not documented 1.43 (1.16–1.76) 0.0008 1.52 (1.21–1.90) 0.0003
HIV diagnosis to care entry
12 months or less Ref Ref Ref Ref
More than 
12 months
1.18 (0.86–1.62) 0.3123 1.32 (0.96–1.83) 0.0916
Not documented 1.92 (1.64–2.24) 0.0001 1.03 (0.86–1.24) 0.7452
Clinical stage
WHO stage 1&2 Ref Ref Ref Ref
WHO stage 3&4 0.76 (0.62–0.94) 0.0119 0.83 (0.66–1.05) 0.1222
Not documented 14.5 (12.1–17.5) 0.0001 10.5 (8.03–13.6) 0.0001
CD4 count
0–100 1.30 (0.81–2.10) 0.2802 1.633 (1.003–
2.658)
0.0486
101–200 1.22 (0.73–2.04) 0.442 1.42 (0.85–2.37) 0.1856
201–250 0.69 (0.32–1.51) 0.3579 0.73 (0.34–1.60) 0.4358
251–350 Ref Ref Ref Ref
351–500 1.45 (0.96–2.18) 0.0796 1.51 (1.00–2.29) 0.0506
>500 2.09 (1.43–3.05) 0.0001 2.14 (1.46–3.14) 0.0001
Not documented 5.86 (4.03–8.52) 0.0001 2.98 (2.00–4.44) 0.0001
Table 3 continued




HR (95% CI) p value HR (95% CI) p value
Opportunistic infections (OI) 
Any OI 0.49 (0.41–0.57) 0.0001 0.91 (0.76–1.10) 0.3419
Italic values indicate statistically significant (p < 0.05) adjusted Hazard Ratios 
with corresponding 95%Confidence Intervals
a Other patient source includes out-patient, KNH CCC and others. PMTCT 
prevention of mother to child transmission
VCT voluntary counselling and testing; TB tuberculosis
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needs could help to mitigate attrition, especially among 
socially vulnerable patients.
The strengths of this study include the reasonably large 
sample size which rendered sufficient power for pre-
cise effect estimates, and the long duration of follow up 
which allowed for trends analyses over time. Study limi-
tations are inherent in the data source. We used routinely 
collected clinical data, which is more prone to errors, 
including missing information [21].
Conclusions
We have documented an upward trend in numbers of 
adolescents and youth entering care. Upstream, this may 
point to increasing new infections in this age category; and 
therefore the need to re-examine HIV prevention inter-
ventions to better target adolescent and young people’s 
needs. Down-stream, HIV care and treatment programs 
may need to better prepare to deliver care to adolescents 
and youth. Overall, the proportion of patients enrolling in 
care with early HIV increased over time. This is expected 
to translate into better treatment outcomes and the need 
for less intense monitoring at the initiation of ART, thereby 
releasing valuable resources to the few vulnerable patients 
at risk of early mortality and severe disease.
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